Question

I am a breastfeeding mother and i want to know if it is safe to use EINECS 211-428-4? Is EINECS 211-428-4 safe for nursing mother and child? Does EINECS 211-428-4 extracts into breast milk? Does EINECS 211-428-4 has any long term or short term side effects on infants? Can EINECS 211-428-4 influence milk supply or can EINECS 211-428-4 decrease milk supply in lactating mothers?

EINECS 211-428-4 lactation summary

EINECS 211-428-4 is dangerous in breastfeeding
  • DrLact safety Score for EINECS 211-428-4 is 7 out of 8 which is considered Dangerous as per our analyses.
  • A safety Score of 7 indicates that usage of EINECS 211-428-4 may cause toxic or severe side effects in breastfed baby.
  • Our study of different scientific research indicates that EINECS 211-428-4 may cause moderate to high side effects or may affect milk supply in lactating mother.
  • Our suggestion is to use safer alternate options rather than using EINECS 211-428-4 .
  • Usage of EINECS 211-428-4 is in contradiction to breastfeeding hence if it is must to use EINECS 211-428-4 and there is no better alternative available then breastfeeding shall be stopped permanently or temporarily.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About EINECS 211-428-4 usage in lactation

Drug is cleared from the body in 6 elimination half-lives. Resuming breastfeeding is likely safe after 3 pump-and-dump days. Regular milk expression and disposition to keep production and avoiding breast plethora or mastitis is desirable.

Alternate Drugs for Antineoplastic agents. ATC L01

Busulfan(Dangerous)
Cisplatin(Unsafe)
Cyclophosphamide(Dangerous)
Doxorubicin(Dangerous)
Etoposide(Dangerous)
Hydroxyurea(Low Risk)
Mitoxantrone(Dangerous)
Vincristine(Dangerous)
Methotrexate(Low Risk)
Imatinib(Unsafe)
Trastuzumab(Unsafe)
Bevacizumab(Low Risk)
Rituximab(Low Risk)
Alemtuzumab(Low Risk)
Fluorouracil(Dangerous)
Paclitaxel(Dangerous)
Carboplatin(Dangerous)
Cetuximab(Unsafe)
Ipilimumab(Unsafe)
Everolimus(Unsafe)
Thioguanine(Dangerous)
Dacarbazine(Dangerous)
Vinorelbine(Dangerous)
Bleomycin(Dangerous)
Vinblastine(Dangerous)
Nivolumab(Unsafe)
Nilotinib(Unsafe)
Dasatinib(Unsafe)
Cladribine(Dangerous)
Erlotinib(Unsafe)
Pazopanib(Unsafe)
Capecitabine(Dangerous)
Docetaxel(Dangerous)
Carmustine(Dangerous)
Exemestane(Dangerous)
Gemcitabine(Dangerous)
Dactinomycin(Dangerous)
Epirubucin(Dangerous)
Idarubicin-Hcl(Dangerous)
Ifosfamide(Dangerous)
Melphalan(Dangerous)
Mitomycin(Dangerous)
Oxaliplatin(Dangerous)
Pentostatin(Dangerous)
Procarbazine(Dangerous)
Teniposide(Dangerous)
Thiotepa(Dangerous)
Tretinoin Oral(Dangerous)
Altretamine(Dangerous)
Anastrozole(Dangerous)
Arsenic-Trioxide(Dangerous)
Asparaginase(Dangerous)
Bexarotene(Dangerous)
Cytarabine(Dangerous)
Chlorambucil(Dangerous)
Chlormethine(Dangerous)
Daunorubicin(Dangerous)
Rubidomycin(Dangerous)
Amethopterin(Low Risk)
Vlb(Dangerous)
Mechlorethamine(Dangerous)
5-ALA(Low Risk)
5-Fu(Dangerous)
MTX(Low Risk)
Daunomycin(Dangerous)
Actinomycin D(Dangerous)
Deoxycoformycin(Dangerous)
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.